



# Invesco Funds Series 3 Interim Report (Unaudited)

For the six months ended 31 May 2018



---

**Invesco Global Health Care Fund**

---

01-02	Investment Policy and Description of Series	04	Price and Income Record
03	Investment Adviser's Report on behalf of the Manager	05-06	Portfolio Statement
04	Fund Performance	07	Changes in the Composition of the Portfolio

---

**Invesco Global Technology Fund**

---

01-02	Investment Policy and Description of Series	09	Price and Income Record
08	Investment Adviser's Report on behalf of the Manager	10-11	Portfolio Statement
09	Fund Performance	12	Changes in the Composition of the Portfolio
13	Statement of Financial Position 31 May 2018	19	Statement of Changes in Net Assets attributable to holders of Redeemable Participating Shares 31 May 2017
14	Statement of Financial Position 30 November 2017	20-26	Notes to the Financial Statements
16	Income Statement 31 May 2018	27	Statement of the Manager's and Depositary's Responsibilities
17	Income Statement 31 May 2017	28	Additional Information
18	Statement of Changes in Net Assets attributable to holders of Redeemable Participating Shares 31 May 2018	29-30	General Information

## Investment Policy and Description of Series

### Investment Objectives and Policies

Invesco Global Health Care Fund (the "Fund") aims to achieve long-term capital growth by investing in healthcare companies throughout the world. The Manager ("Invesco Global Asset Management DAC") will invest principally in four different sectors of the healthcare market, these being pharmaceuticals, biotechnology, healthcare services and medical technology and supplies. The Manager will seek to achieve the investment objective by investing primarily in equity or equity related securities. At least 70% of the Fund's Net Asset value ("NAV") (without taking into account ancillary liquid assets) will be invested in healthcare companies throughout the world.

Invesco Global Technology Fund (the "Fund") aims to achieve long-term capital growth by investing in technology companies throughout the world. For the purposes of the Fund, a technology company is one which operates in fields such as information processing (including computer systems, software development, communication systems and instrumentation development), telecommunications, information services, internet related technology and services, medical and healthcare technology and general electronics. The Manager will seek to achieve the investment objective by investing primarily in equity or equity related securities. At least 70% of the Fund's NAV (without taking into account ancillary liquid assets) will be invested in technology companies throughout the world. While the technological capability and quality of product is an important factor in investment selection, the decisive factor in selecting investments will be the confidence that the Manager has in the ability of the relevant company's management to achieve its goals and objectives. The Fund may invest in any recognised Market.

### Description of the Series

The Invesco Funds Series 3 (the "Series") is a multi-portfolio Irish unit trust comprising Invesco Global Health Care Fund and Invesco Global Technology Fund (the "Funds"). The Series is authorised by the Central Bank of Ireland (the "Central Bank") as an undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities ("UCITS")) Regulations 2011, as amended (the "UCITS Regulations") and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2015 (the "Central Bank UCITS Regulations"). The Series is also authorised by the Hong Kong Securities and Futures Commission (SFC) under the Hong Kong Securities and Futures Ordinance (Cap. 571) and has been recognised by the Financial Conduct Authority under Section 264 of the Financial Services and Markets Act 2000 (the "Act").

The Funds also endeavour to comply with regulatory standards of the other jurisdictions where the Funds are authorised for distribution.

The Funds issue units to unitholders. As per the consolidated prospectus, these units are referred to as "Shares" and the unitholder is referred to as the "Shareholder" throughout these Financial Statements.

Each Fund is a fund in the Invesco range of Funds managed by Invesco Global Asset Management DAC, ("the Manager"). Invesco Global Asset Management DAC is an indirect wholly-owned subsidiary of Invesco Ltd.

Each Fund is approved by the Central Bank of Ireland. Each Fund is also approved by the SFC. In giving authorisation for the Funds the SFC does not take responsibility for the financial soundness of a fund nor for the correctness of any statements made or opinions expressed in this regard.

The Funds are not registered under the United States Investment Company Act of 1940 (as amended) and Shares in the Funds ("Shares") have not been registered under the United States Securities Act of 1933 (as amended). Accordingly, Shares may not be offered, sold or delivered in the United States or to US Persons as defined in the current Prospectus of the Series (the "Prospectus").

The contents of this report, for which the Directors of the Manager are responsible, have been approved by Invesco Global Asset Management DAC, which is regulated by the Central Bank in Ireland.

Share prices are available through the Invesco internet site [www.invesco.com](http://www.invesco.com) (for Shareholders in Hong Kong please refer to [www.invesco.com.hk](http://www.invesco.com.hk)) and, if required by local law or regulation, published in local leading financial newspapers including, in the case of Hong Kong, the Hong Kong Economic Times, the South China Morning Post and the Hong Kong Economic Journal. Share prices are currently also available from Reuters and Bloomberg.

Any investment in the Funds should be considered long-term. There can be no guarantee that the amounts subscribed for Shares will be ultimately realised. Changes in rates of exchange between currencies may cause the value of an investment in the Funds to diminish or increase.

This report to Shareholders does not constitute an offer or invitation to purchase Shares in either of the Funds.

An updated Consolidated Prospectus for Invesco Funds Series 1, 2, 3, 4, 5, 6 and the Invesco Fund Series was issued on 12 December 2017. This contains all current and relevant information (as at the date of issue) regarding the Series and other Funds within the Invesco Funds Series 1, 2, 3, 4, 5, 6 and the Invesco Fund Series. This report to Shareholders has been prepared on the basis of the Prospectus. If you wish to receive a copy of this Prospectus please contact any Invesco office.

### Charges

Share	Launch Date	Annual Management Fee	Annual Distributor Fee	Annual Administration Fee	Annual Depository Fee
		%	%	%	%
<b>Invesco Global Health Care Fund</b>					
'A-AD' Shares <sup>AA</sup>	01/03/1994	2.00	-	0.40	0.006375
'B-AD' Shares <sup>AA</sup>	07/04/2000	2.00	1.00	0.30	0.006375
'C-AD' Shares <sup>AA</sup>	03/03/1994	1.50	-	0.30	0.006375
'Z-AD' Shares <sup>AA</sup>	21/08/2013	1.00	-	0.30	0.006375
<b>Invesco Global Technology Fund</b>					
'A-AD' Shares <sup>AA</sup>	03/01/1993	1.50	-	0.30	0.006375
'B-AD' Shares <sup>AA</sup>	07/04/2000	1.50	1.00	0.30	0.006375
'C-AD' Shares <sup>AA</sup>	13/01/1993	1.00	-	0.30	0.006375
'Z-AD' Shares <sup>AA</sup>	21/08/2013	0.75	-	0.30	0.006375

### Distribution Frequency

<sup>AA</sup> = Annual

The Manager's annual fee is based on the daily net asset value ("NAV") of both Funds and is paid monthly. The Manager will also be paid a fee in respect of the duties as Administrator ("Invesco Global Asset Management DAC") and Registrar ("Invesco Global Asset Management DAC") for each Fund. The Administration fee will be calculated daily and will be paid monthly on the last business day of each month at the rates set out above based on the NAV of each Share Class of each Fund on each business day. The charges are deductible from the income of each Fund or from capital in the event of an income shortfall.

The Manager may pay a portion of its administration fees to the Sub-Administrator ("BNY Mellon Fund Services (Ireland) Designated Activity Company") in consideration for the Sub-Administrator providing certain administrative functions to the Funds.

BNY Mellon Trust Company (Ireland) Limited (the "Depository") will be paid a fee calculated on a sliding scale to a maximum rate of 0.0075% per annum of the NAV of each class of each Share of the Fund on the last business day of the month and paid monthly.

---

## Investment Policy and Description of Series (continued)

---

### Description of the Series (continued)

The assets of a Fund are exclusively available to satisfy the rights of Shareholders in relation to that Fund and the rights of creditors whose claims have arisen in connection with the creation, operation or liquidation of that Fund.

### Investment Adviser's Report on behalf of the Manager

During the six months to end 31 May 2018, the Fund's 'A' Shares returned 1.74% (US\$, total return), outperforming its benchmark, the MSCI World Health Care Index, which returned 0.12%. The Fund lagged its peer group sector, which had an average return of 3.79%, putting the Fund in the second quartile for the period.

Throughout calendar year 2017, major US stock market indexes reached new highs and the market experienced little volatility. Improving economic data, strong corporate profits and the prospect of tax reform legislation contributed to steadily rising stock market indexes. But in early 2018, volatility returned to the US stock and bond markets. Worries about how rising interest rates might affect economic growth and, more recently, concerns about a potential trade war and heightened geopolitical tensions, caused the US stock market to pull back and, starting in February 2018, volatility to increase. In April 2018, the yield on the 10-year US Treasury bond climbed above 3% - a psychologically important level - for the first time since December 2013. Throughout the reporting period, economic data remained generally positive, corporate earnings remained strong and consumer sentiment remained positive. The tone of the Fed's statements grew more hawkish regarding the potential for additional rate increases in 2018. Overseas, economic data were mixed, prompting the European Central Bank and central banks in China and Japan, among other countries, to maintain extraordinarily accommodative monetary policies. Health care stocks (as measure by the MSCI World Health Care Index) were flat.

For the Fund, stock selection and an overweight in the biotechnology industry was the largest contributor to Fund performance relative to the benchmark. Also aiding relative performance was stock selection in the managed health care and life science tools and services industries. The largest detractors were holdings within the health care equipment and health care supplies industries. In addition, certain holdings in the pharmaceuticals industry failed to deliver and were a drag on overall fund performance. Pharmaceuticals are currently the fund's largest underweight. Fundamentals for large capitalization pharmaceuticals are mixed with tepid top-line growth driven by patent expirations, biosimilars, competitive risks and dividend yield in an increasing rate environment.

The largest individual contributor to the Fund's return was Loxo Oncology, a company focused on developing medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. The company's shares increased sharply due to a pairing of their TRK inhibitor drug with Bayer. In addition the company delivered best in class data with their RET inhibitor. Also contributing to performance was Sarepta Therapeutics Inc. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. This includes the discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). During the reporting period, the company produced multiple datapoints during clinical trials increasing their probability of success for their DMD gene therapy program.

The largest detractor during the period was dental equipment maker Dentsply Sirona Inc. which underperformed after delivering lower-than-expected synergies in several key segments and experiencing a series of leadership changes. Also hampering the stock price was tepid market growth the broader dental industry. Also lagging was Bristol-Myers Squibb Co. The company delivered mixed data on new drug Opdivo. Also, the growing belief that Bristol is not a takeover candidate for Pfizer hampered performance.

In addition, during the reporting period, Celgene Corp. reported weaker-than-expected sales of its psoriasis drug Otezla and reduced its future earnings guidance based on declining in sales of the drug.

The Fund's largest relative and absolute exposure was in the biotechnology industry where we believe valuations are attractive, growth is robust, pipelines are strong, and there is pipeline and takeout optionality not priced into the stocks. The Fund did reduce this exposure and took profits on some of the larger holdings.

Dated: 20 June 2018 - Invesco Global Asset Management DAC

## Invesco Global Health Care Fund

Fund Performance (All expressed in the share class base currency, mid to mid, gross income reinvested)	Ccy	Percentage change over:		
		Last 6 months	Last 12 months	Last 5 years (Cumulative)
Invesco Global Health Care Fund 'A-AD' Shares	USD	1.74	7.17	35.52
Invesco Global Health Care Fund 'B-AD' Shares	USD	1.29	6.21	29.55
Invesco Global Health Care Fund 'C-AD' Shares	USD	2.03	7.81	39.65
Invesco Global Health Care Fund 'Z-AD' Shares	USD	2.32	8.35	n/a
MSCI World HealthCare Index (benchmark)	USD	0.12	6.31	7.18
Morningstar GIF OS Sector Equity Health Care*	USD	3.79	10.61	9.70

Source: Morningstar

\* For comparative purposes

The NAV Information for 31 May 2018, 30 November 2017 and 30 November 2016 can be found on page 15.

### Price and Income Record

The table below shows the highest and lowest NAV prices of Shares in the Funds in the last 10 years. There has never been an annual income distribution of the Fund since its launch.

The Fund was redomiciled to Ireland on 15 September 1995 at a price of \$18.96 per Share, excluding all managers' initial charges.

Calendar Year	Highest NAV Price	Lowest NAV Price	Highest NAV Price	Lowest NAV Price	Highest NAV Price	Lowest NAV Price	Highest NAV Price	Lowest NAV Price
	'A-AD' Shares	'A-AD' Shares	'B-AD' Shares	'B-AD' Shares	'C-AD' Shares	'C-AD' Shares	'Z-AD' Shares	'Z-AD' Shares
	USD	USD	USD	USD	USD	USD	USD	USD
2009	65.62	44.80	59.64	41.03	71.07	48.30	n/a	n/a
2010	68.52	58.14	62.06	52.49	74.35	63.22	n/a	n/a
2011	77.35	61.54	69.38	55.09	84.47	67.30	n/a	n/a
2012	81.50	67.55	72.20	60.25	89.75	74.04	n/a	n/a
2013	108.04	78.56	94.65	69.44	119.87	86.64	11.24	9.94
2014	128.55	105.78	111.68	92.42	143.40	117.55	13.49	11.03
2015	148.70	119.04	128.45	102.64	166.50	133.46	15.71	12.60
2016	130.22	105.16	112.80	90.37	147.05	118.16	13.89	11.17
2017	134.03	111.59	113.49	95.19	152.09	126.00	14.48	11.95
2018†	136.78	120.84	115.50	101.88	155.51	137.53	14.83	13.13

† Figures to 30 June 2018.

Source: Invesco Global Asset Management DAC.

Distributions, if any, are paid annually to 'A-AD', 'B-AD', 'C-AD' and 'Z-AD' Shareholders on or after 11 December and are set out in Note 9. Reports on the progress of the Fund are published on or before 31 March and 31 July each year and shall be made available to Shareholders free of charge on request.

The price of Shares and the income from them can go down as well as up. Please note that past performance is not necessarily a guide to future performance.

# Invesco Global Health Care Fund

## Portfolio Statement

As at 31 May 2018

The Portfolio of Investments - (analysed by industrial sector) (Ordinary shares quoted unless otherwise stated)		Fair Value	Value of Fund
Investment	Holding	\$	%
<b>PHARMACEUTICALS (37.16%) (30 November 2017: 33.24%)</b>			
Aclaris Therapeutics Inc	124,888	2,236,744	0.55
Aerie Pharmaceuticals Inc	38,773	1,960,944	0.48
Allergan Plc	36,971	5,600,922	1.37
Array BioPharma Inc	265,457	4,256,603	1.04
Ascendis Pharma A/S	29,536	2,167,204	0.53
AstraZeneca Plc	371,843	13,711,711	3.35
Bayer AG	88,383	10,536,345	2.57
Bristol-Myers Squibb Co	77,621	4,115,854	1.00
Clovis Oncology Inc	72,860	3,459,028	0.84
DBV Technologies SA	194,491	4,532,613	1.11
Dermira Inc	113,284	985,004	0.24
Eli Lilly & Co	127,935	10,730,548	2.62
Heron Therapeutics Inc	95,706	3,108,052	0.76
Jazz Pharmaceuticals Plc	20,234	3,409,732	0.83
Johnson & Johnson	129,842	15,710,882	3.84
Merck & Co Inc	174,483	10,424,487	2.55
Momenta Pharmaceuticals Inc	122,779	2,922,140	0.71
Neurocrine Biosciences Inc	37,263	3,564,020	0.87
Nippon Shinyaku Co Ltd	61,800	4,430,697	1.08
Novartis AG	213,997	16,204,923	3.96
Novo Nordisk A/S	198,591	9,471,650	2.31
Odonate Therapeutics Inc	89,551	2,103,105	0.51
Roche Holding AG	26,797	5,833,881	1.42
Sarepta Therapeutics Inc	33,208	3,136,330	0.77
Supernus Pharmaceuticals Inc	66,536	3,817,503	0.93
TESARO Inc	36,347	1,615,806	0.39
Zogenix Inc	50,745	2,152,857	0.53
		152,199,585	37.16
<b>HEALTHCARE-PRODUCTS (22.15%) (30 November 2017: 16.74%)</b>			
Abbott Laboratories	137,877	8,559,404	2.09
Align Technology Inc	14,069	4,663,100	1.14
Baxter International Inc	97,191	6,983,659	1.71
Boston Scientific Corp	258,354	7,881,089	1.92
DENTSPLY SIRONA Inc	163,145	7,414,125	1.81
Edwards Lifesciences Corp	30,068	4,133,298	1.01
Inspire Medical Systems Inc	42,374	1,259,355	0.31
Medtronic Plc	79,410	6,821,319	1.67
Olympus Corp	110,800	3,926,084	0.96
Siemens Healthineers AG	68,450	2,677,066	0.65
Thermo Fisher Scientific Inc	80,592	16,999,673	4.15
Wright Medical Group NV	273,164	6,881,001	1.68
Zimmer Biomet Holdings Inc	112,953	12,499,944	3.05
		90,699,117	22.15
<b>BIOTECHNOLOGY (18.61%) (30 November 2017: 27.20%)</b>			
ACADIA Pharmaceuticals Inc	57,817	1,047,933	0.26
Alexion Pharmaceuticals Inc	70,150	8,169,318	1.99
Amarin Corp Plc	415,382	1,401,914	0.34
Amicus Therapeutics Inc	185,683	3,159,396	0.77
Assembly Biosciences Inc	18,727	787,564	0.19
BioCryst Pharmaceuticals Inc	204,003	1,331,120	0.33
Biogen Inc	33,045	9,727,787	2.38
BioMarin Pharmaceutical Inc	97,050	8,793,701	2.15
Bluebird Bio Inc	18,029	3,295,250	0.80
Celgene Corp	70,145	5,468,153	1.34
Exact Sciences Corp	80,474	4,714,569	1.15
Illumina Inc	15,547	4,234,536	1.03

## Invesco Global Health Care Fund

### Portfolio Statement (continued)

As at 31 May 2018

The Portfolio of Investments - (analysed by industrial sector) (Ordinary shares quoted unless otherwise stated)		Fair Value \$	Value of Fund %
Investment	Holding		
<b>BIOTECHNOLOGY (18.61%) (30 November 2017: 27.20%) (continued)</b>			
Incyte Corp	44,781	3,038,839	0.74
Loxo Oncology Inc	12,774	2,217,886	0.54
REGENXBIO Inc	52,069	2,811,726	0.69
Seattle Genetics Inc	36,992	2,100,591	0.51
Shire Plc	37,078	6,089,135	1.49
Vertex Pharmaceuticals Inc	49,845	7,806,475	1.91
		76,195,893	18.61
<b>HEALTHCARE-SERVICES (15.93%) (30 November 2017: 16.45%)</b>			
Anthem Inc	34,368	7,960,488	1.95
Centene Corp	63,176	7,504,677	1.83
Cigna Corp	21,673	3,756,581	0.92
Envision Healthcare Corp	69,875	3,042,707	0.74
Eurofins Scientific SE	8,110	4,292,839	1.05
HCA Healthcare Inc	51,148	5,365,681	1.31
Humana Inc	42,318	12,544,325	3.06
Notre Dame Intermedica Participacoes SA	318,156	1,841,065	0.45
UnitedHealth Group Inc	77,187	18,912,745	4.62
		65,221,108	15.93
<b>ELECTRONICS (1.81%) (30 November 2017: 1.65%)</b>			
Agilent Technologies Inc	34,307	2,150,706	0.53
Koninklijke Philips NV	126,358	5,249,110	1.28
		7,399,816	1.81
<b>COMMERCIAL SERVICES (1.69%) (30 November 2017: 1.01%)</b>			
HealthEquity Inc	42,653	3,327,147	0.81
HMS Holdings Corp	116,777	2,550,410	0.62
Qualicorp SA	203,000	1,039,237	0.26
		6,916,794	1.69
<b>INSURANCE (0.62%) (30 November 2017: Nil)</b>			
Hapvida Participacoes e Investimentos SA	318,100	2,549,277	0.62
<b>RETAIL (0.42%) (30 November 2017: 0.64%)</b>			
Raia Drogasil SA	103,000	1,719,767	0.42
<b>SOFTWARE (0.11%) (30 November 2017: Nil)</b>			
Ping An Healthcare and Technology Co Ltd	76,400	446,818	0.11
<b>OPEN-ENDED FUNDS (1.90%) (30 November 2017: 3.17%)</b>			
Short-Term Investments Company (Global Series) Plc - US Dollar Liquidity Portfolio Agency Class†	7,778,596	7,778,596	1.90
<b>Total Value of Investments (Cost \$349,173,816)</b>		<b>411,126,771</b>	<b>100.40</b>
† Investment Funds (see note 3 for full details)			
<b>Total Financial Assets</b>		<b>411,126,771</b>	<b>100.40</b>
<b>Cash and Cash Equivalents (see Note 5 and Note 6 for details)</b>		<b>1,049,097</b>	<b>0.26</b>
<b>Bank Overdraft (see Note 5 and Note 6 for details)</b>		<b>(32,871)</b>	<b>(0.01)</b>
<b>Other Net Current Liabilities</b>		<b>(2,636,552)</b>	<b>(0.65)</b>
<b>Total Value of the Fund at 31 May 2018</b>		<b>409,506,445</b>	<b>100.00</b>
			<b>% of</b>
			<b>Total Assets</b>
Analysis of total assets			
Transferable securities admitted to an official stock exchange listing or dealt in on another regulated market.			97.71
Collective investment scheme			1.88
Other assets			0.41
			100.00



## Invesco Global Health Care Fund

### Changes in the Composition of the Portfolio

For the six months ended 31 May 2018

<b>Purchases</b>	<b>Cost \$</b>	<b>Sales</b>	<b>Proceeds \$</b>
Short-Term Investments Company (Global Series) Plc -		Short-Term Investments Company (Global Series) Plc -	
US Dollar Liquidity Portfolio Agency Class	96,147,906	US Dollar Liquidity Portfolio Agency Class	103,134,441
Johnson & Johnson	16,048,502	Aetna Inc	18,344,487
Novo Nordisk A/S	11,130,791	Celgene Corp	14,079,674
Abbott Laboratories	8,419,446	Gilead Sciences Inc	11,131,114
AstraZeneca Plc	7,430,729	Bristol-Myers Squibb Co	10,005,689
Medtronic Plc	7,170,770	Shire Plc	6,295,452
Baxter International Inc	7,112,737	Alexion Pharmaceuticals Inc	5,555,186
Cigna Corp	4,257,356	Align Technology Inc	4,787,171
Eurofins Scientific SE	4,177,176	BioMarin Pharmaceutical Inc	4,553,864
UnitedHealth Group Inc	2,911,692	Thermo Fisher Scientific Inc	4,160,539
Zimmer Biomet Holdings Inc	2,897,912	Cigna Corp	4,058,137
Amicus Therapeutics Inc	2,657,289	Exact Sciences Corp	3,940,965
Siemens Healthineers AG	2,426,898	Molina Healthcare Inc	3,837,248
Momenta Pharmaceuticals Inc	2,283,034	Tenet Healthcare Corp	3,518,476
Odonate Therapeutics Inc	2,242,344	Biogen Inc	3,401,305
Hapvida Participacoes e Investimentos SA	2,165,123	Eli Lilly & Co	3,274,538
HMS Holdings Corp	2,094,006	Illumina Inc	3,230,001
Ascendis Pharma A/S	1,951,491	ResMed Inc	3,022,546
DBV Technologies SA	1,840,181	Ultragenyx Pharmaceutical Inc	2,819,184
Notre Dame Intermedica Participacoes SA	1,680,880	Bluebird Bio Inc	2,712,961
Other Purchases	8,729,811	Sarepta Therapeutics Inc	2,710,053
<b>Total cost of purchases since 01 December 2017</b>	<b>195,776,074</b>	Other Sales	41,448,546
		<b>Total proceeds of sales since 01 December 2017</b>	<b>260,021,577</b>

---

## Invesco Global Technology Fund

---

### Investment Adviser's Report on behalf of the Manager

During the six month period ending 31 May 2018, the Fund's 'A' Shares returned 11.30% (US\$, total return) outperforming its benchmark, the NASDAQ Composite Total Return Index and peer group the GIF OS Equity Technology sector, which returned 8.83% and 8.18% respectively during the same period.

For the six month period ending May 31, 2018, global equity markets posted modest gains. The first quarter of 2018 saw the return of significant volatility with global markets experiencing their biggest swings in over a year. After delivering strong positive returns for most of January, global equities sold off sharply in February as rising inflation levels spurred concern that central banks would have to raise interest rates at a faster pace than previously expected. Global equities rebounded in April on the back of rising oil prices; however, volatility returned in May as political uncertainty in Italy influenced market moves.

For the reporting period as a whole, the information technology (IT) and energy sectors led performance. In contrast, the telecommunication services sector and more defensive sectors such as consumer staples and utilities underperformed.

Relative outperformance was driven by security selection in the internet & direct marketing retail, I.T services and communications equipment industries. Overweight exposure versus the index in the software and internet & direct marketing retail industries also contributed to relative performance. In contrast, stock selection in the semiconductors & semiconductor equipment industry was the key detractor from both absolute and relative performance. Underweight exposure versus the index in the technology hardware, storage & peripherals industry detracted from relative performance as well.

At the end of the period, the Fund's largest overweight exposures relative to the NASDAQ Composite Index were in the software, internet software & services and IT services industries. By contrast, the Fund's largest underweight exposures were in the biotechnology, computers & peripherals and commercial banking industries.

We attempt to harness multi-year secular trends, which should benefit long-term investors regardless of near-term economic strength. Current areas of emphasis are those expected to take market share from mature technology, including the game-changing technologies of mobile, security, cloud and biopharmaceuticals.

We remain optimistic about prospects for IT spending given strong enterprise balance sheets and their need to invest in new technologies. We also believe the increased pace of health care innovation will continue to drive attractive long-term growth rates.

Dated: 20 June 2018 - Invesco Global Asset Management DAC

## Invesco Global Technology Fund

Fund Performance (All expressed in share class base currency, mid to mid, gross income reinvested)	Ccy	Percentage change over:		
		Last 6 months	Last 12 months	Last 5 years (Cumulative)
Invesco Global Technology Fund 'A-AD' Shares	USD	11.30	22.17	97.49
Invesco Global Technology Fund 'B-AD' Shares	USD	10.73	20.90	87.66
Invesco Global Technology Fund 'C-AD' Shares	USD	11.56	22.73	102.35
Invesco Global Technology Fund 'Z-AD' Shares	USD	11.69	23.02	n/a
NASDAQ Composite Index (benchmark)	USD	8.83	21.34	128.46
Morningstar GIF OS Sector Equity Technology*	USD	8.18	22.38	96.26

Source: Morningstar

\*For comparative purposes

The NAV Information for 31 May 2018, 30 November 2017 and 30 November 2016 can be found on page 15.

### Price and Income Record

The table below shows the highest and lowest NAV prices of Shares in the Funds in the last 10 years. There has never been an annual income distribution on the Fund since its launch.

The Fund was redomiciled to Ireland on 15 March 1993 at a price of \$52.69 per Share, excluding all managers' initial charges.

Calendar Year	Highest NAV Price 'A-AD' Shares USD	Lowest NAV Price 'A-AD' Shares USD	Highest NAV Price 'B-AD' Shares USD	Lowest NAV Price 'B-AD' Shares USD	Highest NAV Price 'C-AD' Shares USD	Lowest NAV Price 'C-AD' Shares USD	Highest NAV Price 'Z-AD' Shares USD	Lowest NAV Price 'Z-AD' Shares USD	
	2009	9.62	5.44	8.68	4.96	10.43	5.88	n/a	n/a
	2010	11.26	8.58	10.06	7.71	12.27	9.33	n/a	n/a
2011	12.51	9.32	11.16	8.28	13.64	10.19	n/a	n/a	
2012	12.58	10.28	11.11	9.02	13.80	11.31	n/a	n/a	
2013	13.77	10.87	11.94	9.53	15.23	11.97	11.14	9.83	
2014	15.59	13.21	13.39	11.42	17.32	14.63	12.70	10.71	
2015	16.55	14.26	14.17	12.15	18.45	15.91	13.54	11.69	
2016	16.59	12.77	14.11	10.84	18.53	14.28	13.62	10.50	
2017	21.93	15.51	18.28	13.06	24.74	17.41	18.27	12.83	
2018†	24.68	20.76	20.46	17.30	27.92	23.42	20.65	17.30	

† Figures to 30 June 2018.

Source: Invesco Global Asset Management DAC.

Distributions, if any are paid annually to 'A-AD', 'B-AD', 'C-AD' and 'Z-AD' Shareholders on or after 11 December and are set out in Note 9. Reports on the progress of the Fund are published on or before 31 March and 31 July each year and shall be made available to Shareholders free of charge on request.

The price of Shares and the income from them can go down as well as up. Please note that past performance is not necessarily a guide to future performance.

# Invesco Global Technology Fund

## Portfolio Statement

As at 31 May 2018

The Portfolio of Investments - (analysed by industrial sector) (Ordinary shares quoted unless otherwise stated)		Fair Value \$	Value of Fund %
Investment	Holding		
<b>INTERNET (32.55%) (30 November 2017: 27.15%)</b>			
Alibaba Group Holding Ltd	45,769	9,062,948	5.55
Alphabet Inc Class A	6,953	7,489,389	4.58
Alphabet Inc Class C	2,780	2,967,970	1.82
Amazon.com Inc	9,717	15,793,089	9.67
Baidu Inc	9,011	2,177,283	1.33
Booking Holdings Inc	921	1,932,272	1.18
Facebook Inc	43,245	8,115,357	4.97
Netflix Inc	7,193	2,542,689	1.55
Palo Alto Networks Inc	14,791	3,101,451	1.90
		53,182,448	32.55
<b>SOFTWARE (22.70%) (30 November 2017: 17.19%)</b>			
Activision Blizzard Inc	69,305	4,898,824	3.00
Adobe Systems Inc	7,550	1,867,870	1.14
Electronic Arts Inc	40,119	5,270,834	3.22
Microsoft Corp	81,010	8,013,509	4.90
salesforce.com Inc	27,409	3,543,024	2.17
Sea Ltd	114,693	1,677,385	1.03
ServiceNow Inc	10,954	1,955,125	1.20
Take-Two Interactive Software Inc	47,944	5,304,285	3.25
Ubisoft Entertainment SA	42,443	4,556,185	2.79
		37,087,041	22.70
<b>SEMICONDUCTORS (8.98%) (30 November 2017: 10.94%)</b>			
Applied Materials Inc	60,259	3,108,461	1.90
ASML Holding NV	16,369	3,225,593	1.97
Broadcom Inc	9,494	2,367,281	1.45
Integrated Device Technology Inc	122,983	4,175,888	2.56
NVIDIA Corp	7,087	1,792,834	1.10
		14,670,057	8.98
<b>DIVERSIFIED FINANCIAL SERVICES (5.22%) (30 November 2017: 4.92%)</b>			
Mastercard Inc	18,112	3,472,342	2.12
Visa Inc	38,738	5,059,764	3.10
		8,532,106	5.22
<b>COMPUTERS (4.94%) (30 November 2017: 7.96%)</b>			
Apple Inc	43,021	8,066,437	4.94
<b>HEALTHCARE-PRODUCTS (4.70%) (30 November 2017: 3.48%)</b>			
Intuitive Surgical Inc	5,745	2,640,718	1.61
Stryker Corp	15,383	2,693,409	1.65
Thermo Fisher Scientific Inc	11,137	2,349,183	1.44
		7,683,310	4.70
<b>HEALTHCARE-SERVICES (4.38%) (30 November 2017: 3.43%)</b>			
IQVIA Holdings Inc	16,550	1,663,027	1.02
UnitedHealth Group Inc	22,447	5,500,076	3.36
		7,163,103	4.38
<b>TOYS/GAMES/HOBBIES (3.64%) (30 November 2017: 4.03%)</b>			
Nintendo Co Ltd	14,500	5,941,891	3.64
<b>HOME FURNISHINGS (2.80%) (30 November 2017: 3.74%)</b>			
Sony Corp	96,600	4,573,059	2.80
<b>BIOTECHNOLOGY (2.66%) (30 November 2017: 4.89%)</b>			
Alexion Pharmaceuticals Inc	17,017	1,981,715	1.21
BioMarin Pharmaceutical Inc	15,823	1,433,722	0.88
Celgene Corp	11,953	931,796	0.57
		4,347,233	2.66
<b>TELECOMMUNICATIONS (2.26%) (30 November 2017: 2.87%)</b>			
Cisco Systems Inc	86,034	3,686,127	2.26

## Invesco Global Technology Fund

### Portfolio Statement (continued)

As at 31 May 2018

The Portfolio of Investments - (analysed by industrial sector) (Ordinary shares quoted unless otherwise stated)	Fair Value	Value of Fund
Investment	\$	%
Investment	Holding	%
<b>COMMERCIAL SERVICES (1.81%) (30 November 2017: 0.52%)</b>		
Equifax Inc	7,193	0.51
PayPal Holdings Inc	26,046	1.30
	<b>2,948,866</b>	<b>1.81</b>
<b>AEROSPACE/DEFENSE (1.61%) (30 November 2017: 2.23%)</b>		
Raytheon Co	12,415	1.61
<b>MEDIA (0.96%) (30 November 2017: 3.32%)</b>		
Charter Communications Inc	5,887	0.96
<b>ELECTRONICS (0.50%) (30 November 2017: 0.73%)</b>		
Keysight Technologies Inc	15,345	0.50
<b>PHARMACEUTICALS (Nil) (30 November 2017: 1.38%)</b>		
<b>OPEN-ENDED FUNDS (0.19%) (30 November 2017: 1.03%)</b>		
Short-Term Investments Company (Global Series) Plc - US Dollar Liquidity Portfolio Agency Class†	315,819	0.19
<b>Total Value of Investments (Cost \$111,605,706)</b>	<b>163,218,049</b>	<b>99.90</b>
† Investment Funds (see note 3 for full details)		
<b>Total Financial Assets</b>	<b>163,218,049</b>	<b>99.90</b>
<b>Cash and Cash Equivalents (see Note 5 and Note 6 for details)</b>	<b>697,160</b>	<b>0.43</b>
<b>Other Net Current Liabilities</b>	<b>(537,689)</b>	<b>(0.33)</b>
<b>Total Value of the Fund at 31 May 2018</b>	<b>163,377,520</b>	<b>100.00</b>
		<b>% of</b>
<b>Analysis of total assets</b>		<b>Total Assets</b>
Transferable securities admitted to an official stock exchange listing or dealt in on another regulated market.		99.32
Collective investment scheme		0.19
Other assets		0.49
		<b>100.00</b>

## Invesco Global Technology Fund

### Changes in the Composition of the Portfolio

For the six months ended 31 May 2018

Purchases	Cost \$	Sales	Proceeds \$
Short-Term Investments Company (Global Series) Plc - US		Short-Term Investments Company (Global Series) Plc -	
Dollar Liquidity Portfolio Agency Class	35,760,065	US Dollar Liquidity Portfolio Agency Class	37,017,212
Alibaba Group Holding Ltd	4,647,395	Apple Inc	4,214,555
Facebook Inc	2,956,648	Broadcom Ltd	4,120,912
PayPal Holdings Inc	2,110,393	Alibaba Group Holding Ltd	3,107,867
UnitedHealth Group Inc	2,000,353	Sony Corp	2,826,488
Applied Materials Inc	1,893,695	Facebook Inc	2,742,195
Micron Technology Inc	1,875,627	Comcast Corp	2,215,210
Microsoft Corp	1,826,859	Allergan Plc	1,990,942
Adobe Systems Inc	1,724,451	Sprint Corp	1,961,957
Activision Blizzard Inc	1,702,285	First Data Corp	1,919,293
Cisco Systems Inc	1,698,335	Celgene Corp	1,798,565
Philip Morris International Inc	1,691,389	Amgen Inc	1,737,050
Baidu Inc	1,688,849	Amazon.com Inc	1,678,689
Take-Two Interactive Software Inc	1,659,420	Applied Materials Inc	1,598,010
Sony Corp	1,645,753	Micron Technology Inc	1,497,923
ASML Holding NV	1,573,095	DISH Network Corp	1,497,172
Electronic Arts Inc	1,426,797	Visa Inc	1,460,313
Broadcom Ltd	1,359,992	Philip Morris International Inc	1,384,876
Palo Alto Networks Inc	1,149,274	ASML Holding NV	1,337,983
Stryker Corp	1,134,282	Mastercard Inc	1,332,217
Mastercard Inc	1,094,342	Raytheon Co	1,244,424
Comcast Corp	1,046,468	Microsoft Corp	956,721
Visa Inc	1,008,067	Alphabet Inc Class A	937,311
Alphabet Inc Class C	930,104	Other Sales	10,662,507
IQVIA Holdings Inc	920,637	<b>Total proceeds of sales since 01 December 2017</b>	<b>91,240,392</b>
Other Purchases	7,229,005		
<b>Total cost of purchases since 01 December 2017</b>	<b>83,753,580</b>		

## Statement of Financial Position

As at 31 May 2018

	Notes	Invesco Global Health Care Fund \$	Invesco Global Technology Fund \$
<b>Assets</b>			
Cash and cash equivalents	5/6	1,049,097	697,160
Amounts due on creations		306,548	-
Financial assets at fair value through profit or loss		411,126,771	163,218,049
Other accrued income and prepaid expenses		320,064	94,934
<b>Total assets</b>		<b>412,802,480</b>	<b>164,010,143</b>
<b>Liabilities</b>			
Bank overdraft	5/6	(32,871)	-
Pre-funded trades		(17,216)	(198,704)
Amounts due on liquidations		(2,981,250)	(324,491)
Management fee payable		(145,964)	(43,466)
Administrator's fee payable		(28,604)	(5,878)
Accrued expenses		(90,130)	(60,084)
<b>Total liabilities (excluding net assets attributable to holders of redeemable participating Shares)</b>		<b>(3,296,035)</b>	<b>(632,623)</b>
<b>Net assets attributable to holders of redeemable participating Shares</b>		<b>409,506,445</b>	<b>163,377,520</b>

The accompanying Notes 1 to 13 on pages 20 to 26 form part of these Financial Statements.

---

## Statement of Financial Position

As at 30 November 2017

---

	Invesco Global Health Care Fund \$	Invesco Global Technology Fund \$
<b>Assets</b>		
Cash and cash equivalents	1,829,826	559,923
Balances due from brokers	-	2,234,733
Amounts due on creations	277,309	155,045
Financial assets at fair value through profit or loss	465,594,363	152,495,756
Other accrued income and prepaid expenses	132,039	78,243
<b>Total assets</b>	<b>467,833,537</b>	<b>155,523,700</b>
<b>Liabilities</b>		
Pre-funded trades	(36,637)	(7,408)
Balances due to brokers	-	(2,314,152)
Amounts due on liquidations	(1,777,823)	(152,171)
Management fee payable	(687,539)	(170,631)
Administrator's fee payable	(136,988)	(35,054)
Accrued expenses	(82,104)	(52,184)
<b>Total liabilities (excluding net assets attributable to holders of redeemable participating Shares)</b>	<b>(2,721,091)</b>	<b>(2,731,600)</b>
<b>Net assets attributable to holders of redeemable participating Shares</b>	<b>465,112,446</b>	<b>152,792,100</b>

---



## Statement of Financial Position

		31 May 2018			30 November 2017			30 November 2016		
		Total NAV in sub-fund currency Total	Number of Shares in issue	NAV per Share in class currency	Total NAV in sub-fund currency Total	Number of Shares in issue	NAV per Share in class currency	Total NAV in sub-fund currency Total	Number of Shares in issue	NAV per Share in class currency
<b>Invesco Global Health Care Fund (USD)</b>										
A-AD	USD	219,615,206	1,690,427	129.92	249,485,839	1,953,611	127.70	281,227,290	2,450,358	114.77
B-AD	USD	18,705	171	109.38	18,469	171	107.99	16,747	171	97.92
C-AD	USD	188,777,631	1,275,522	148.00	214,375,964	1,477,988	145.05	212,952,626	1,643,463	129.58
Z-AD	USD	1,094,903	77,432	14.14	1,232,174	89,140	13.82	496,433	40,391	12.29
<b>Invesco Global Technology Fund (USD)</b>										
A-AD	USD	92,830,868	3,927,030	23.64	91,800,793	4,321,636	21.24	68,260,104	4,252,860	16.05
B-AD	USD	11,150	569	19.61	10,069	569	17.71	8,644	640	13.52
C-AD	USD	70,484,261	2,636,417	26.73	60,962,377	2,543,887	23.96	52,141,345	2,894,002	18.02
Z-AD	USD	51,241	2,592	19.77	18,861	1,065	17.70	14,145	1,065	13.28

## Income Statement

For the six months ended 31 May 2018

	Notes	Invesco Global Health Care Fund \$	Invesco Global Technology Fund \$
<b>Income</b>			
Interest income		5,687	2,134
Dividend income		3,099,049	558,138
Net gain on financial assets and liabilities at fair value through profit or loss (realised and unrealised)	8	9,765,668	18,198,013
<b>Total investment income</b>		<b>12,870,404</b>	<b>18,758,285</b>
<b>Expenses</b>			
Management fee		(3,822,050)	(1,025,299)
Administrator's fee		(764,926)	(238,399)
Depositary fee		(13,791)	(5,067)
Safekeeping and servicing fee		(8,800)	(3,105)
Auditor's fee		(11,199)	(9,149)
Other operating expenses		(49,204)	(34,607)
<b>Total operating expenses</b>		<b>(4,669,970)</b>	<b>(1,315,626)</b>
<b>Operating profit</b>		<b>8,200,434</b>	<b>17,442,659</b>
<b>Finance costs</b>			
Bank overdraft interest		(1,385)	(49)
<b>Total finance costs</b>		<b>(1,385)</b>	<b>(49)</b>
<b>Profit before tax</b>		<b>8,199,049</b>	<b>17,442,610</b>
Withholding tax		(772,265)	(118,721)
Net decrease in provision for unrealised capital gains tax		(15,167)	-
<b>Increase in net assets attributable to holders of redeemable participating Shares</b>		<b>7,411,617</b>	<b>17,323,889</b>

The accompanying Notes 1 to 13 on pages 20 to 26 form part of these Financial Statements.

The Funds had no recognised gains or losses in the financial period other than those dealt with in the Income Statement. Gains and losses arose solely from operations during the period ended 31 May 2018.

## Income Statement

For the six months ended 31 May 2017

	Invesco Global Health Care Fund \$	Invesco Global Technology Fund \$
<b>Income</b>		
Interest income	37,717	2,776
Dividend income	3,548,465	482,246
Other income	172	-
Net gain on financial assets and liabilities at fair value through profit or loss (realised and unrealised)	31,025,063	23,223,236
<b>Total investment income</b>	<b>34,611,417</b>	<b>23,708,258</b>
<b>Expenses</b>		
Management fee	(4,313,693)	(771,275)
Administrator's fee	(863,174)	(179,111)
Depositary fee	(15,396)	(3,807)
Safekeeping and servicing fee	(5,933)	(1,596)
Auditor's fee	(7,092)	(5,848)
Other operating expenses	(80,364)	(22,133)
<b>Total operating expenses</b>	<b>(5,285,652)</b>	<b>(983,770)</b>
<b>Operating profit</b>	<b>29,325,765</b>	<b>22,724,488</b>
<b>Finance costs</b>		
Bank overdraft interest	(2,024)	(8)
<b>Total finance costs</b>	<b>(2,024)</b>	<b>(8)</b>
<b>Profit before tax</b>	<b>29,323,741</b>	<b>22,724,480</b>
Withholding tax	(954,452)	(109,653)
<b>Increase in net assets attributable to holders of redeemable participating Shares</b>	<b>28,369,289</b>	<b>22,614,827</b>

## Statement of Changes in Net Assets Attributable to Holders of Redeemable Participating Shares

For the six months ended 31 May 2018

	Invesco Global Health Care Fund \$	Invesco Global Technology Fund \$
<b>Net assets attributable to holders of redeemable participating Shares at beginning of period</b>	<b>465,112,446</b>	<b>152,792,100</b>
Increase in net assets attributable to holders of redeemable participating Shares	7,411,617	17,323,889
<b>Share Transactions</b>		
Proceeds from redeemable participating Shares issued	12,383,614	26,838,255
Cost of redeemable participating Shares redeemed	(75,401,232)	(33,576,724)
<b>Net assets attributable to holders of redeemable participating Shares at the end of period</b>	<b>409,506,445</b>	<b>163,377,520</b>

The accompanying Notes 1 to 13 on pages 20 to 26 form part of these Financial Statements.

## Statement of Changes in Net Assets Attributable to Holders of Redeemable Participating Shares

For the six months ended 31 May 2017

	Invesco Global Health Care Fund \$	Invesco Global Technology Fund \$
<b>Net assets attributable to holders of redeemable participating Shares at beginning of period</b>	<b>494,693,096</b>	<b>120,424,238</b>
Increase in net assets attributable to holders of redeemable participating Shares	28,369,289	22,614,827
<b>Share Transactions</b>		
Proceeds from redeemable participating Shares issued	17,510,935	9,436,081
Cost of redeemable participating Shares redeemed	(77,531,365)	(22,564,735)
<b>Net assets attributable to holders of redeemable participating Shares at the end of period</b>	<b>463,041,955</b>	<b>129,910,411</b>

# Notes to the Financial Statements

For the six months ended 31 May 2018

## 1. Significant Accounting Policies

### (a) Basis of Preparation

The condensed financial statements have been prepared under the historical cost convention as modified by the revaluation of financial assets and financial liabilities held at fair value through profit or loss.

These condensed financial statements have been prepared in accordance with accounting standards generally accepted in Ireland (Irish GAAP) including Financial Reporting Standard ("FRS") 104 "Interim Financial Reporting" and the European Communities (UCITS) Regulations, 2011, as amended (the "UCITS Regulations") and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) ("UCITS") Regulations 2015, as amended (the "Central Bank UCITS Regulations"). These condensed financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with the annual financial statements for the year ended 30 November 2017, which have been prepared in accordance with accounting standards generally accepted in Ireland.

Subject to shareholder's approval, the Board of the Manager plans to merge the existing sub-funds within the Invesco Funds Series 3 into the Invesco Funds (Luxembourg SICAV), during the financial year ending 30 November 2018. Once approved, the Board of the Manager intends to merge the sub-funds of the Series into specifically launched sub-funds (shell funds) or where appropriate, sub-funds that already exist. Accordingly, the financial statements have been prepared on a non-going concern basis. The decision to wind down the Series has no impact on the measurement or recognition of the sub-funds' assets and liabilities.

### Investments

The Funds classify their investments in transferable securities and money market instruments as financial assets at fair value through profit or loss. For the purpose of determining the redemption value of the redeemable participating Shares in the Portfolios, the investments held by the Portfolios are valued at fair value. Under Financial Reporting Standard 102, in accounting for all of its financial instruments, an entity is required to apply either:

(a) the full requirements of Sections 11 "Basic Financial Instruments" and Section 12 "Other Financial Instruments Issues" of FRS 102, or

(b) the recognition and measurement provisions of International Accounting Standards 39 "Financial Instruments: Recognition and Measurement" ("IAS 39") as adopted for use in the European Union and the disclosure requirements of Sections 11 and 12, or

(c) the recognition and measurement provisions of International Financial Reporting Standards ("IFRS") 9 "Financial Instruments" and the disclosure requirements of Sections 11 and 12.

The Funds have elected to apply the recognition and measurement provisions of IAS 39 and the disclosure requirements of Sections 11 and 12. In normal market conditions, the difference between the two valuation bases is not significant.

The Funds have availed of the exemption permitted to open-ended investment funds under FRS102, Section 7 "Statement of Cash Flows" not to prepare a cash flow statement.

Dividends, interest and capital gains received on investments made by the Funds may be subject to withholding taxes imposed by the country from which the investment income/gains are received and such taxes may not be recoverable by the Funds or its Shareholders.

### (b) Foreign Currency Translation

#### (i) Functional and presentation currency

Items included in each Fund's Financial Statements are measured using the currency of the primary economic environment in which it operates ("the functional currency"). This is the US Dollar (\$). The US Dollar is also the presentation currency.

The Financial Statements are presented in the Funds' functional and presentation currency and rounded to the nearest whole number. They are prepared on the fair value basis for financial assets and financial liabilities at fair value through profit or loss and derivative financial instruments. Other financial assets and financial liabilities are stated at amortised cost or redemption amount (redeemable Shares).

(ii) Assets and liabilities in foreign currencies are translated into US Dollars at the rates of exchange ruling at the Statement of Financial Position date. Income and expenditure transactions are translated at the rates of exchange ruling at the date of the transactions.

The principal exchange rates used: US\$1.00

	31 May 2018	30 November 2017	31 May 2017
Australian Dollar	1.32	1.32	1.34
Brazilian Real	3.72	3.26	3.26
Canadian Dollar	1.28	1.29	1.34
Czech Koruna	22.10	21.53	23.58
Danish Krone	6.37	6.29	6.63
Egyptian Pound	17.92	17.68	18.12
Euro	0.86	0.84	0.89
Hong Kong Dollar	7.85	7.81	7.79
Indian Rupee	67.48	64.48	64.52
Indonesian Rupiah	13,895.00	13,526.00	13,320.00
Japanese Yen	108.94	112.33	110.78
Malaysian Ringgit	3.98	4.09	4.28
New Zealand Dollar	1.43	1.46	1.41
Nigeria Naira	360.75	360.50	314.75
Norwegian Kroner	8.17	8.29	8.43
Philippine Peso	52.54	50.26	49.77
Pound Sterling	0.75	0.74	0.78
Singapore Dollar	1.34	1.35	1.38
South African Rand	12.57	13.61	13.09
South Korean Won	1,077.95	1,088.25	1,119.60
Swedish Krona	8.79	8.38	8.72
Swiss Franc	0.99	0.99	0.97
Taiwan Dollar	29.96	29.99	30.08
Thailand Baht	31.99	32.66	34.06
Turkish Lira	4.51	3.94	3.53
Uruguay Peso	31.05	28.94	28.23

To determine the NAV of each Fund for subscriptions and redemptions, investments have been valued based on the mid market prices at 12.00pm (Irish time) on the relevant trading day. For Financial Statements purposes, investments are valued based on mid market prices.

---

## Notes to the Financial Statements (Continued)

For the six months ended 31 May 2018

---

### 2. UK Reporting

The offshore Funds (Tax) Regulations 2009 and Subsequent Regulations Amendments (“the Regulations”) introduced new provisions to update offshore funds regime and came into effect for periods of accounting commencing after 1 December 2009. The Reporting Funds Regime requires:

1. The reporting fund status is applied for once and in advance.
2. The relevant Share classes to report details of income annually, within six months of their accounting year end to both Investors and UK authorities.
3. Investors to provide details of reportable income on their annual tax return.

The following Share Classes currently have UK Reporting Status;

<u>Fund</u>	<u>Classes</u>
Invesco Global Health Care Fund	A-Dist, C-Dist & Z-Dist
Invesco Global Technology Fund	A-Dist, C-Dist & Z-Dist

The Statement of Reportable Income for the financial year ended 30 November 2017 is available through the following Invesco website.  
[www.invesco.com](http://www.invesco.com)

---

### 3. Soft Commissions and Related Party Transactions

The Funds, (consistent with obtaining the best net result, including best execution), may enter into agreements with counterparties whereby those counterparties may make payments for investment services provided to the Funds.

Investment services are used by the Funds to improve or add to the services provided to its clients. Although each and every service may not be used to service each and every account managed by the Funds, the Directors of the Manager consider that those investment services received are, in the aggregate, of significant assistance in fulfilling its investment responsibilities and are of demonstrable benefit to all clients. Only services, that in the view of the Directors of the Manager, assist in the provision of investment services to the Funds’ clients will be paid for by counterparties.

Allowable investment services include services that provide assistance to the Funds in their investment performance. Those services include, but are not necessarily limited to, furnishing analysis, research and advisory services including economic factors and trends, portfolio valuation and analysis, performance measurement, market prices services and the use of specialised computer software and hardware or other information facilities.

The Funds will ensure adherence to the investment decision making responsibilities to its clients in accordance with the laws of the countries that have jurisdiction over its clients or business. This may vary in application with respect to the appropriateness of those investment services provided.

The Funds select counterparties to execute transactions on the basis that transactions will only be executed provided the placing of orders will not operate against the best interest of the Fund’s clients and that the multiple is at a level which is generally accepted market practice. The Funds will endeavour to obtain best execution on all transactions for all clients.

In addition, clients may direct the Funds to pay commission to counterparties for products and services that would otherwise have to be paid for. In such cases, the commission is used for the exclusive benefit of the client whose transactions generated that commission.

The Manager, Administrator and Global Distributor (Invesco Global Asset Management DAC) are deemed to be Related Parties under FRS 102. Fees charged, out of the Fund, by the Manager and Administrator are disclosed in the Income Statement on page 16. Amounts payable at the period end are disclosed in the Statement of Financial Position on page 13.

The Manager may pay a portion of its administration fees to BNY Mellon Fund Services (Ireland) Designated Activity Company (the “Sub-Administrator”), in consideration for the Sub-Administrator providing certain administration functions to the Funds. Fees for the Global Distributor are paid from the Management fee and fees paid to the Registrar are paid from Administration fee.

Invesco Global Health Care Fund and Invesco Global Technology Fund invest in the following Invesco managed Fund - the Short-Term Investments Company (Global Series) Plc - US Dollar Liquidity Portfolio Agency Class is deemed to be a Related Person under Financial Reporting Standard 8 because the Manager is Invesco Global Asset Management DAC.

The Manager, Invesco Global Asset Management DAC is a wholly owned subsidiary of Invesco UK Limited, which is a wholly owned subsidiary of Invesco Limited, the group parent company.

Directors Fees are not paid by the Funds during the period under review. Directors fees are paid by Invesco Global Asset Management DAC.

There were no Director’s holdings in the Funds for the period ended 31 May 2018 and the year ended 30 November 2017.

## Notes to the Financial Statements (Continued)

For the six months ended 31 May 2018

### 3. Soft Commissions and Related Party Transactions (continued)

Invesco UK Limited, held a beneficial interest in the Shares representing approximately the following percentages of the total number of Shares in issue of the relevant fund class:

#### Seed Capital

Invesco UK Limited held the following Redeemable Participating Shares in the Funds and class as detailed below:

	Number of Shares at the start of the Period	Number of Shares acquired in the Period	Number of Shares redeemed in the Period	Number of Shares at Period end	Percentage of Total Shares
<b>For the Period Ended 31 May 2018</b>					
Invesco Global Health Care Fund 'B-AD' Shares	65	–	–	65	38
Invesco Global Health Care Fund 'C-AD' Shares	–	102	–	102	0
Invesco Global Health Care Fund 'Z-AD' Shares	700	–	–	700	1
Invesco Global Technology Fund 'A-AD' Shares	–	636	–	636	0
Invesco Global Technology Fund 'Z-AD' Shares	700	–	–	700	27
	Number of Shares at the start of the year	Number of Shares acquired in the year	Number of Shares redeemed in the year	Number of Shares at year end	Percentage of Total Shares
<b>For the Year Ended 30 November 2017</b>					
Invesco Global Health Care Fund 'B-AD' Shares	65	–	–	65	38
Invesco Global Health Care Fund 'Z-AD' Shares	700	–	–	700	1
Invesco Global Technology Fund 'Z-AD' Shares	700	–	–	700	66

### 4. Fair Value Estimation

The Funds have adopted the amendments to FRS 102 – "Fair Value Hierarchy Disclosures", which is effective for accounting periods beginning on or after 1 January 2017.

The fair value of financial assets and liabilities traded in active markets (such as publicly trading securities) are based on quoted market prices at 12.00pm (Irish time) on 31 May 2018 for Financial Statement purposes.

The quoted market price used for financial assets held by the Funds is the current mid price. The appropriate quoted market price for financial liabilities is the current asking price.

A financial instrument is regarded as quoted in an active market if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arms length basis.

The Funds are exposed to daily cash redemptions of redeemable Shares. They therefore invest the majority of their assets in investments that are traded in an active market and can be readily disposed of; they invest only a limited proportion of their assets in investments not actively traded on a recognised market.

For instruments for which there is no active market, the Funds may use internally developed models, which are usually based on valuation methods and techniques generally recognised as standard within the industry. Valuation models are used primarily to value unlisted equity instruments for which markets were or have been inactive during the financial period. Some of the inputs to these models may not be market observable and are therefore estimated based on assumptions. The output of a model is always an estimate or approximation of a value that cannot be determined with certainty, and valuation techniques employed may not fully reflect all factors relevant to the positions the Funds hold. Valuations are therefore adjusted, where appropriate, to allow for additional factors including model risk, liquidity risk and counterparty risk.

The carrying value of other receivables and payables are assumed to approximate their fair values.

The Funds classify fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements.

The fair value hierarchy has the following levels:

- Quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1).
- Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (Level 2).
- Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs) (Level 3).



## Notes to the Financial Statements (Continued)

For the six months ended 31 May 2018

### 4. Fair Value Estimation (continued)

The level in the fair value hierarchy within which the fair value measurement is categorised in its entirety is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety.

If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

The determination of what constitutes observable requires significant judgement by the Directors of the Manager. The Funds consider observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities. Because of the inherent uncertainties of valuation, the values reflected in the Financial Statements may materially differ from the value received upon actual sale of those investments.

The following tables analyse within the fair value hierarchy the Funds' financial assets and liabilities measured at fair value in accordance with FRS102 and FRED 62 Amendments to FRS 102 - Fair Value Hierarchy Disclosures.

#### 31 May 2018

<b>Invesco Global Health Care Fund</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
Financial assets designated at fair value through profit or loss at inception:				
Equity securities	\$ 411,126,771	\$ -	\$ -	\$ 411,126,771
<b>Total Investments</b>	<b>411,126,771</b>	<b>-</b>	<b>-</b>	<b>411,126,771</b>

<b>Invesco Global Technology Fund</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
Financial assets designated at fair value through profit or loss at inception:				
Equity securities	\$ 163,218,049	\$ -	\$ -	\$ 163,218,049
<b>Total Investments</b>	<b>163,218,049</b>	<b>-</b>	<b>-</b>	<b>163,218,049</b>

#### 30 November 2017

<b>Invesco Global Health Care Fund</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
Financial assets designated at fair value through profit or loss at inception:				
Equity securities	\$ 465,594,363	\$ -	\$ -	\$ 465,594,363
<b>Total Investments</b>	<b>465,594,363</b>	<b>-</b>	<b>-</b>	<b>465,594,363</b>

<b>Invesco Global Technology Fund</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
Financial assets designated at fair value through profit or loss at inception:				
Equity securities	\$ 152,495,756	\$ -	\$ -	\$ 152,495,756
<b>Total Investments</b>	<b>152,495,756</b>	<b>-</b>	<b>-</b>	<b>152,495,756</b>

Investments whose values are based on quoted market prices in active markets, and therefore classified within Level 1, include active listed equities, debt securities and exchange traded derivatives. The Funds do not adjust the quoted price for these instruments.

Financial instruments that trade in markets that are not considered to be active but are valued based on quoted market prices, dealer quotations or alternative pricing sources supported by observable inputs are classified within Level 2. These include, investment-grade corporate bonds listed and over-the-counter derivatives. As Level 2 investments include positions that are not traded in active markets and/or are subject to transfer restrictions, valuations may be adjusted to reflect illiquidity and/or non-transferability, which are generally based on available market information.

Investments classified within Level 3 have significant unobservable inputs, as they trade infrequently. Level 3 instruments include corporate debt securities. As observable prices are not available for these securities, the Funds have used valuation techniques to derive the fair value.

The Funds also consider original transaction price, recent transactions in the same or similar instruments and completed third-party transactions in comparable instruments. The Funds also consider other liquidity, credit and market risk factors. The Manager may, with the consent of the Depositary, adjust the model as deemed necessary.

## Notes to the Financial Statements (Continued)

For the six months ended 31 May 2018

### 5. Cash and Cash Equivalents

	Credit Ratings		Invesco Global	Invesco Global
	S&P	Moody's	Health Care Fund \$	Technology Fund \$

31 May 2018

Cash balances on deposits and bank overdrafts are listed below at the Statement of Financial Position date:

The Bank of New York Mellon	A-1+	P-1	1,016,226	697,160
-----------------------------	------	-----	-----------	---------

Within the amounts held with The Bank of New York Mellon above \$32,871 is included as unsecured bank overdraft in Invesco Global Health Care Fund.

	Credit Ratings		Invesco Global	Invesco Global
	S&P	Moody's	Health Care Fund \$	Technology Fund \$

30 November 2017

Cash balances on deposits and bank overdrafts are listed below at the Statement of Financial Position date:

The Bank of New York Mellon	A-1+	P-1	1,829,826	559,923
-----------------------------	------	-----	-----------	---------

### 6. Umbrella Cash Collection Accounts

The Investor Money Regulations 2015 for Fund Service Providers (the "Investor Money Regulations" or "IMR") established under the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)), requires the Series to channel subscription, distribution and redemption monies through an Investors Money Collection Account. As a result subscription and redemption monies will be channeled through an umbrella cash collection account in the name of the Series and, in respect of any sub-funds considered to be highly leveraged, sub-fund cash collection accounts in the name of the relevant sub-fund(s). Pending issue of the Shares and / or payment of subscription proceeds to an account in the name of the Series or the relevant Funds, and pending payment of redemption proceeds or distributions, the relevant investor will be an unsecured creditor of the relevant Fund in respect of amounts paid by or due to it. For the avoidance of doubt the Funds of the Series are not considered highly leveraged.

	Credit Ratings		Invesco Global	Invesco Global
	S&P	Moody's	Health Care Fund \$	Technology Fund \$

31 May 2018

The Bank of New York Mellon	A-1+	P-1	17,216	198,704
-----------------------------	------	-----	--------	---------

	Credit Ratings		Invesco Global	Invesco Global
	S&P	Moody's	Health Care Fund \$	Technology Fund \$

30 November 2017

The Bank of New York Mellon	A-1+	P-1	36,637	7,408
-----------------------------	------	-----	--------	-------

The positive balances are included in the Statement of Financial Position within Cash and cash equivalents and Amounts due on creations. The overdrawn positions are included in the Statement of Financial Position within Bank overdraft and Pre-funded trades.

### 7. Stock Lending

The stock lending agreement is with State Street Bank Europe Limited. The income earned in the current period is \$Nil (31 May 2017: \$Nil) for Invesco Global Health Care Fund and \$Nil (31 May 2017: \$Nil) for Invesco Global Technology Fund. There were no loan positions at period ended 31 May 2018. Non-cash collateral received was in the form of German, French, Belgian and Dutch government bonds. The Fund also received US Treasury bonds. The income earned from stock lending is received by the Fund net of a 15% fee, which is retained by State Street Bank for providing the Service.

There were no securities held for stock lending as at 31 May 2018 and 30 November 2017.

## Notes to the Financial Statements (Continued)

For the six months ended 31 May 2018

### 8. Net Gains and Losses on Investments and Currency

	Realised and unrealised gains/(losses) charged to Income Statement 31 May 2018 \$	Realised and unrealised gains/(losses) charged to Income Statement 31 May 2017 \$
<b>Invesco Global Health Care Fund</b>		
Equities	9,777,911	30,957,875
Forward currency contracts	(13,031)	(825)
Currency	1,582	68,490
Transaction costs	(794)	(477)
	<b>9,765,668</b>	<b>31,025,063</b>

	Realised and unrealised gains/(losses) charged to Income Statement 31 May 2018 \$	Realised and unrealised gains/(losses) charged to Income Statement 31 May 2017 \$
<b>Invesco Global Technology Fund</b>		
Equities	18,209,106	23,227,455
Forward currency contracts	(8,502)	(28,416)
Currency	292	26,046
Transaction costs	(2,883)	(1,849)
	<b>18,198,013</b>	<b>23,223,236</b>

### 9. Distribution to 'A-AD', 'B-AD', 'C-AD' and 'Z-AD' Shareholders

There were no distributions on Invesco Global Health Care Fund and Invesco Global Technology Fund for the six months ended 31 May 2018 and year ended 30 November 2017.

### 10. Efficient Portfolio Management

Forward foreign currency exchange contracts may be used to hedge against anticipated future changes in exchange rates which otherwise might either adversely affect the value of the Funds' portfolio securities or adversely affect the price of securities which the Funds intend to purchase at a later date. Forward currency contracts are fair valued at the prevailing forward rate at the reporting date. The resulting unrealised gains and losses for the period are included in the Statement of Financial Position and the Income Statement. Realised gains or losses on maturity are presented in the Income Statement.

The Funds may also engage in forward currency transactions and utilise futures and options for efficient portfolio management or hedging purposes under the conditions and within the limits laid down by the Central Bank and, if more restrictive, the Securities and Futures Commission.

There were no forward currency contracts, futures or options held by the Invesco Global Technology Fund and the Invesco Global Health Care Fund during the six months ended 31 May 2018 or the year ended 30 November 2017.

Please refer to Note 7 for details relating to Stock Lending.

---

## Notes to the Financial Statements (Continued)

For the six months ended 31 May 2018

---

### 11. Significant Events During the Period

An updated Consolidated Prospectus for Invesco Fund Series 1, 2, 3, 4, 5, 6 and the Invesco Funds Series was issued on 12 December 2017.

The Prospectus has been updated to reflect changes in the following areas:

MiFID II Requirements  
German Investment Tax Act (GITA) Requirements  
EMIR Requirements  
Adjustments to Z Share Class Access

There were no other significant events during the period ended 31 May 2018.

---

### 12. Subsequent Events

There were no subsequent events since the period ended 31 May 2018, that could have an effect on these Financial Statements.

---

### 13. Approval of Financial Statements

The Financial Statements were approved by the Directors of the Manager on 16 July 2018.

---

## Statement of the Manager's and Depositary's Responsibilities

The Manager is required under the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended (the "UCITS Regulations"), to prepare Financial Statements for each financial period reporting the financial position of each Fund in the Invesco Funds Series 3 ("the Series") as at the end of the accounting period and of its income/excess of expenditure over income for the period. In preparing those Financial Statements, the Manager:

- ensures that the Financial Statements comply with the Trust Deed, FRS 102 and applicable accounting standards subject to any material departures which are disclosed and explained in the Financial Statements;
- selects suitable accounting policies and then applies them consistently;
- makes judgements and estimates that are reasonable and prudent;
- prepares the Financial Statements on the going concern basis unless it is inappropriate to presume that the Series will continue in operation; and
- is responsible for taking reasonable steps for the prevention and detection of fraud, error, or non-compliance with laws or the UCITS Regulations, and other irregularities.

The Manager is required to keep proper accounting records and to manage the Series in accordance with the UCITS Regulations, the Hong Kong Code on Unit Trusts, Mutual Funds and the Trust Deed.

The Directors of the Manager of the Series are responsible for the maintenance and integrity of the information related to the Series on the Invesco website. Information on the internet is accessible in many countries with different legal requirements. Legislation in Ireland governing the preparation and dissemination of Financial Statements may differ from legislation in other jurisdictions.

The Directors of the Manager are satisfied that there are arrangements (evidenced by written procedures) in place, to ensure that the obligations set out in the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended, and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2015, as amended are applied to all transactions with connected persons. All transactions with connected persons are at arms length.

The Directors of the Manager are satisfied that transactions with connected parties entered into during the period complied with the obligations set out in the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended, and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2015, as amended. A connected person is defined as the promoter, manager, depositary, investment adviser and/or associated or group companies of these.

The Depositary is required under the UCITS Regulations to:

1. ensure that the sale, issue, repurchase, redemption and cancellation of Shares effected by or on behalf of the Funds are carried out in accordance with the UCITS Regulations and in accordance with the Trust Deed.
2. ensure that the value of Shares is calculated in accordance with the UCITS Regulations and the Trust Deed.
3. carry out the instructions of the Manager unless they conflict with the UCITS Regulations or the Trust Deed.
4. ensure that where transactions involve the Fund's assets, any consideration is remitted to the Fund within time limits which are acceptable market practice in the context of a such transaction.
5. ensure that the Fund's income is applied in accordance with the UCITS Regulations and the Trust Deed.
6. enquire into the conduct of the Manager in each annual accounting period and report thereon to the Shareholders or Unitholders. The Depositary's report shall be delivered to the Manager in good time to enable the Manager to include a copy of the report in its Annual Report. The Depositary's Report shall state whether in the Depositary's opinion the Funds has been managed in that period:
  - (i) in accordance with the limitations imposed on the investment and borrowing powers of the Manager and Depositary by the Trust Deed and the UCITS Regulations; and
  - (ii) otherwise in accordance with the provisions of the Trust Deed and the UCITS Regulations.

If the Manager does not comply with (i) or (ii) above, the Depositary must state why this is the case and outline the steps which the Depositary has taken to rectify the situation.

The Depositary must notify the Central Bank of Ireland promptly of any material breach of the UCITS Regulations, conditions imposed by the Central Bank of Ireland or provisions of the prospectus with regard to the Funds.

The duties provided for above may not be delegated by the Depositary to a third party. These duties must be carried out in the State.

The Depositary also takes into its custody or under its control all the assets of the Funds and holds them in safekeeping for the Shareholders. The Depositary will provide record keeping and ownership verification services in respect of assets of the Trust not held in custody in accordance with the provisions of the UCITS Directive and the UCITS Regulations. The Depositary will also provide cash monitoring services in respect of each Fund's cash flows and subscriptions.

---

## Additional Information

---

### Remuneration Policy

Invesco Global Asset Management D.A.C. (the "Management Company") has adopted a remuneration policy which is consistent with the principles outlined in the European Securities and Markets Authority (ESMA) Guidelines on sound remuneration policies under the UCITS Directive.

The policy was revised in 2017 to include a detailed process for the determination of Identified Staff and align it to the different EU regulations, specifically in relation to:

- Performance assessment;
- Guaranteed variable remuneration;
- Balance between fixed and variable remuneration;
- Performance adjustment (malus and clawback);
- Deferred stock awards.

The purpose of the remuneration policy is to ensure the remuneration of the staff of the Management Company is consistent with and promotes sound and effective risk management, does not encourage risk-taking which is inconsistent with the risk profiles, rules or instruments of incorporation of the Manager and of the UCITS it manages and does not impair the Management Company's compliance with its duty to act in the best interests of the UCITS it manages. The Management Company's summary remuneration policy is available on our website ([www.invescomanagementcompany.lu](http://www.invescomanagementcompany.lu)). The Management Company's full remuneration policy is available for free from the registered office (see address page 29) upon request.

The remuneration policy is reviewed annually by the Compliance, Human Resources and Risk Management functions who recommend any adjustments to ensure continued alignment of the policy with sound risk management. The board of directors of the Management Company is responsible for the oversight of remuneration and for ensuring adherence to this policy through the Human Resources function.

The Internal Audit function conducts regular testing of administration of the remuneration policy to assess its ongoing compliance with the Invesco Group's remuneration policies and procedures.

The aggregate total remuneration for the staff of the Management Company during performance period ended 2017 (1 January 2017 to 31 December 2017) is EUR 7.60m of which EUR 6.43m is fixed remuneration and EUR 1.17m is variable remuneration. The number of beneficiaries is 82.

The Management Company has identified individuals considered to have a material impact on the risk profile of the Management Company or the UCITS it manages (Identified Staff), who include board members of the Management Company, senior management, heads of control functions, other risk takers and any employees receiving total remuneration that takes them into the same remuneration bracket as senior management and risk takers.

The aggregate total remuneration paid to the Identified Staff of the Management Company for UCITS related activities for the performance period ended 2017 (1 January 2017 to 31 December 2017) is EUR 4.70m of which EUR 1.94m is paid to Senior Management and EUR 2.76m is paid to other Identified Staff. Please note the total remuneration for Identified Staff of the Management Company for UCITS related activities includes remuneration for staff employed by delegates.

### Securities Financing Transactions Regulation

As at 31 May 2018 and 30 November 2017, there were no securities on loan from the Funds.

---

## General Information

---

### Directors of the Manager

L. Schmidt (American)\*  
C. O'Sullivan (Irish)  
W. Manahan (Irish, Independent Director)  
N. Tolchard (British)  
A.M. King (Irish)  
M. Grosclaude (French)

### Global Distributor, Manager and Administrator

Invesco Global Asset Management DAC  
Registered Office  
Central Quay  
Riverside IV  
Sir John Rogerson's Quay  
Dublin 2  
Ireland

### Correspondence address for Global Distributor

c/o International Financial Data Services (Ireland) Limited  
Bishop's Square  
Redmond's Hill  
Dublin 2  
Ireland

### Registrar and Transfer Agent

International Financial Data Services (Ireland) Limited  
Bishop's Square  
Redmond's Hill  
Dublin 2  
Ireland

### Sub-Administrator

BNY Mellon Fund Services (Ireland) Designated Activity Company  
One Dockland Central  
Guild Street  
International Financial Services Centre  
Dublin 1  
Ireland

### Secretary

Invesco Asset Management Limited  
Perpetual Park  
Perpetual Park Drive  
Henley-on-Thames  
Oxfordshire RG9 1HH  
United Kingdom

### Depository

BNY Mellon Trust Company (Ireland) Limited  
One Dockland Central  
Guild Street  
International Financial Services Centre  
Dublin 1  
Ireland

### Hong Kong Sub-Distributor and Representative

Invesco Asset Management Asia Limited  
41/F Champion Tower  
Three Garden Road, Central  
Hong Kong

### Legal Adviser

Matheson  
70 Sir John Rogerson's Quay  
Dublin 2  
Ireland

### Swiss Representative

Invesco Asset Management (Switzerland) Limited  
Talacker 34  
8001 Zurich  
Switzerland

### United Kingdom Representative

Invesco Global Investment Funds Limited  
Perpetual Park  
Perpetual Park Drive  
Henley-on-Thames  
Oxfordshire RG9 1HH  
United Kingdom

### Independent Auditors of the Fund and Management Company Auditors

PricewaterhouseCoopers  
Chartered Accountants  
One Spencer Dock  
North Wall Quay  
Dublin 1  
Ireland

### Investment Advisers

Invesco Advisers, Inc.  
1555 Peachtree Street N.E.  
Atlanta  
Georgia  
GA 30309  
USA

### Austrian Distributor

Invesco Asset Management Österreich - Zweigniederlassung der Invesco Asset Management Deutschland GmbH  
Rotenturmstrasse 16-18  
A-1010 Vienna  
Austria

### Austrian Paying Agent

Erste Bank der oesterreichischen Sparkassen AG  
Am Belvedere 1  
A-1100 Wien  
Austria

### German Information Agent

Invesco Asset Management Deutschland GmbH  
Registered Office  
An der Welle 5  
D-60322 Frankfurt am Main  
Germany

### German Paying Agent

BNP Paribas Securities Services S.C.A.  
Zweigniederlassung Frankfurt am Main  
Europa-Allee 12  
D-60327 Frankfurt  
Germany

The latest Financial Statements are also available through Invesco's Internet Site [www.invesco.com](http://www.invesco.com)

For Shareholders in Hong Kong please refer to [www.invesco.com.hk](http://www.invesco.com.hk)

\*Resigned 6 December 2017

---

## General Information (continued)

---

### **Invesco Limited Representative Offices**

#### **Austria**

Invesco Asset Management Österreich - Zweigniederlassung der  
Invesco Asset Management Deutschland GmbH  
Rotenturmstraße 16-18  
A-1010 Vienna  
Austria  
Tel: +43 1 316 20 00  
Fax: +43 1 316 20 20

#### **Belgium, Norway, Denmark, and Finland**

Invesco Asset Management S.A. Belgian Branch  
235 Avenue Louise  
1050 Brussels  
Belgium  
Tel: +322 641 0170  
Fax: +322 641 0175

#### **France**

Invesco Asset Management S.A.  
18, rue de Londres  
75009 Paris  
France  
Tel: +33 1 56 62 43 00  
Fax: +33 1 56 62 43 83/43 20

#### **Germany**

Invesco Asset Management  
Deutschland GmbH  
An der Welle 5  
D-60322 Frankfurt am Main  
Germany  
Tel: +49 69 29807 0  
Fax: +49 69 29807 159

#### **Hong Kong and Macau**

Invesco Asset Management Asia  
Limited  
41/F Champion Tower  
Three Garden Road, Central  
Hong Kong  
Tel: +852 3128 6000  
Fax: +852 3128 6001

#### **Ireland**

Invesco Global Asset Management DAC  
Registered Office  
Central Quay  
Riverside IV  
Sir John Rogerson's Quay  
Dublin 2  
Ireland  
Tel: +353 1 439 8000  
Fax: +353 1 439 8400

#### **Italy and Greece**

Invesco Asset Management S.A Sede Secondaria  
Via Bocchetto,6  
20123 Milano  
Italy  
Tel: +39 02 88074 1  
Fax: +39 02 88074 391

#### **The Netherlands**

Invesco Asset Management S.A.  
Dutch Branch  
Vinoly Building  
Claude Debussylaan 26  
1082 MD Amsterdam  
Netherlands  
Tel: +31 205 61 62 61  
Fax: +31 205 61 68 88

#### **Spain and Latin America**

Invesco Asset Management S.A.  
Sucursal en España  
Calle Goya 6/3rd Floor  
28001 Madrid  
Spain  
Tel: + 34 91 781 3020  
Fax: + 34 91 576 0520

#### **Sweden**

Invesco Asset Management S.A. (France)  
Swedish Filial  
Stureplan 4c  
4th Floor, Stockholm 11435  
Sweden  
Tel: +46 8 463 1106  
Fax: +46 2 641 01 75



## **Contact Us**

**Invesco Global Asset Management DAC**  
Manager/Global Distributor,  
Registered Office  
Central Quay, Riverside IV,  
Sir John Rogerson's Quay, Dublin 2, Ireland  
Telephone: +353 1 439 8000  
Facsimile: +353 1 439 8400  
Website: [www.invesco.com](http://www.invesco.com)

**Invesco Asset Management Asia Limited**  
Hong Kong Sub-Distributor and Representative  
41/F Citibank Tower  
Three Garden Road, Central  
Hong Kong  
Telephone: + 852 3128 6000  
Facsimile : + 852 3128 6001  
Website: [www.invesco.com.hk](http://www.invesco.com.hk)